241 related articles for article (PubMed ID: 30373888)
1. Impact of somatic and germline mutations on the outcome of systemic mastocytosis.
Muñoz-González JI; Jara-Acevedo M; Alvarez-Twose I; Merker JD; Teodosio C; Hou Y; Henriques A; Roskin KM; Sanchez-Muñoz L; Tsai AG; Caldas C; Matito A; Sánchez-Gallego JI; Mayado A; Dasilva-Freire N; Gotlib JR; Escribano L; Orfao A; García-Montero AC
Blood Adv; 2018 Nov; 2(21):2814-2828. PubMed ID: 30373888
[TBL] [Abstract][Full Text] [Related]
2. Frequency and prognostic impact of
Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Henriques A; Viñas E; Prieto C; Sánchez-Muñoz L; Caldas C; Mayado A; Matito A; Dasilva-Freire N; Orfao A; García-Montero AC
Blood; 2019 Aug; 134(5):456-468. PubMed ID: 31151985
[TBL] [Abstract][Full Text] [Related]
3. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
Jawhar M; Schwaab J; Schnittger S; Meggendorfer M; Pfirrmann M; Sotlar K; Horny HP; Metzgeroth G; Kluger S; Naumann N; Haferlach C; Haferlach T; Valent P; Hofmann WK; Fabarius A; Cross NC; Reiter A
Leukemia; 2016 Jan; 30(1):136-43. PubMed ID: 26464169
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
Nedoszytko B; Arock M; Lyons JJ; Bachelot G; Schwartz LB; Reiter A; Jawhar M; Schwaab J; Lange M; Greiner G; Hoermann G; Niedoszytko M; Metcalfe DD; Valent P
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401724
[TBL] [Abstract][Full Text] [Related]
5. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
Naumann N; Lübke J; Shomali W; Reiter L; Horny HP; Jawhar M; Dangelo V; Fabarius A; Metzgeroth G; Kreil S; Sotlar K; Oni C; Harrison C; Hofmann WK; Cross NCP; Valent P; Radia D; Gotlib J; Reiter A; Schwaab J
Br J Haematol; 2021 Jul; 194(2):344-354. PubMed ID: 34060083
[TBL] [Abstract][Full Text] [Related]
6. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022.
Arock M; Hoermann G; Sotlar K; Hermine O; Sperr WR; Hartmann K; Brockow K; Akin C; Triggiani M; Broesby-Olsen S; Reiter A; Gotlib J; Horny HP; Orfao A; Metcalfe DD; Valent P
J Allergy Clin Immunol; 2022 Jun; 149(6):1855-1865. PubMed ID: 35430191
[TBL] [Abstract][Full Text] [Related]
8. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
[TBL] [Abstract][Full Text] [Related]
10. Response and progression on midostaurin in advanced systemic mastocytosis:
Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
[TBL] [Abstract][Full Text] [Related]
12. Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2016 Apr; 96(4):381-8. PubMed ID: 26095448
[TBL] [Abstract][Full Text] [Related]
13. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression.
Garcia-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Teodosio C; Sanchez-Muñoz L; Muñiz C; Muñoz-Gonzalez JI; Mayado A; Matito A; Caldas C; Morgado JM; Escribano L; Orfao A
Blood; 2016 Feb; 127(6):761-8. PubMed ID: 26622064
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis.
Kristensen T; Vestergaard H; Bindslev-Jensen C; Mortz CG; Kjaer HF; Ollert M; Møller MB; Broesby-Olsen S;
Allergy; 2017 Nov; 72(11):1737-1743. PubMed ID: 28432683
[TBL] [Abstract][Full Text] [Related]
15. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
Naumann N; Jawhar M; Schwaab J; Kluger S; Lübke J; Metzgeroth G; Popp HD; Khaled N; Horny HP; Sotlar K; Valent P; Haferlach C; Göhring G; Schlegelberger B; Meggendorfer M; Hofmann WK; Cross NCP; Reiter A; Fabarius A
Genes Chromosomes Cancer; 2018 May; 57(5):252-259. PubMed ID: 29341334
[TBL] [Abstract][Full Text] [Related]
16. KIT Mutations and Other Genetic Defects in Mastocytosis: Implications for Disease Pathology and Targeted Therapies.
Chantran Y; Valent P; Arock M
Immunol Allergy Clin North Am; 2023 Nov; 43(4):651-664. PubMed ID: 37758404
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
Valent P
Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
[TBL] [Abstract][Full Text] [Related]
18. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.
Schwaab J; Umbach R; Metzgeroth G; Naumann N; Jawhar M; Sotlar K; Horny HP; Gaiser T; Hofmann WK; Schnittger S; Cross NC; Fabarius A; Reiter A
Am J Hematol; 2015 Sep; 90(9):774-7. PubMed ID: 26017288
[TBL] [Abstract][Full Text] [Related]
19. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
Jawhar M; Schwaab J; Hausmann D; Clemens J; Naumann N; Henzler T; Horny HP; Sotlar K; Schoenberg SO; Cross NC; Fabarius A; Hofmann WK; Valent P; Metzgeroth G; Reiter A
Leukemia; 2016 Dec; 30(12):2342-2350. PubMed ID: 27416984
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.
Marton I; Krenács L; Bagdi E; Bakos A; Demeter J; Borbényi Z
Pathol Oncol Res; 2016 Apr; 22(2):293-9. PubMed ID: 26545382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
